Chinese Pharma and Health Sector Sees Over 10 Financing Rounds in February, Multiple Companies Raise Over RMB 100 Million

　　【Pharmaceutical Network Industry Dynamics】According to the author's incomplete statistics, since February 2024, there have been over 10 financing and investment events in China's pharmaceuticals and healthcare sector, including companies such as Evopoint Biosciences and Suzhou Aiyi Animal Medicine Co., Ltd., which have each raised more than 100 million yuan.
 

　Evopoint Biosciences: Completed US$100 Million Series E Financing
 

Recently, Evopoint Biosciences completed a Series E round of financing worth 700 million yuan. Participants in this round of financing included Tencent Investment, Guoxin Investment, Jinan Industrial Development, Huakong Investment, Yuankai Capital, Chenhai Capital, Pudong Venture Capital, and Zhuopu Capital.
 

The funds raised in this round will be mainly used to advance the domestic and international clinical trials of the company's multiple pipelines, enhance the three self-innovative technology platforms of targeted therapy, anti-infection, and PROTAC, accelerate the operation of production bases and the construction of commercialization teams, and promote the early market launch of products to benefit a wide range of patients.
 

It is reported that Evopoint Biosciences has developed an innovative drug pipeline, including BLI inhibitors, EZH2 inhibitors, hURAT1 inhibitors, and next-generation ADCs, covering disease areas such as cancer, multidrug-resistant bacterial infections, and metabolic disorders. Currently, the company has nine products in clinical development stages both in China and internationally, two of which have entered Phase III clinical trials.
 

　　Suzhou Aiyi Animal Medicine Co., Ltd.: Completes Hundreds of Millions of CNY in Series C Financing
 

Recently, Suzhou Aiyi Animal Medicine Co., Ltd. has completed a C-round financing of several hundred million RMB. Participants in this equity financing round include Yuanxi Haihe Fund, Songqing Shenhui Jiarui Fund, Guohai Innovation Capital, Starry Sky Capital, and Jinsajiang United Capital Runpu Fund, among others. In addition to the equity portion, this round of financing also further supplemented the company's long-term capital through a ten-year debt financing.
 

Data shows that Suzhou Aiyi Animal Medicine Co., Ltd. is a company specializing in the research, development, and production of veterinary biological products and veterinary chemical drugs, with projects such as the development of a novel canine distemper vaccine.
 

　　HOPE MEDICINE: Completes RMB 200 Million Series B+ Financing
 

Funding Update: HOPE MEDICINE Completes Nearly 200 Million RMB in Series B+ Round Led by Xichuang Investment and VMS Group
 

It is reported that HOPE MEDICINE (HK) LIMITED is a science-driven innovative biopharmaceutical company at the clinical stage, dedicated to researching, developing, and commercializing first-in-class drugs.
 

　　AccuPulse: Completes RMB 200 Million Series A+ Financing
 

February 7th Update: AccuPulse recently announced the completion of a nearly 200 million yuan A+ round of financing. This round was jointly participated by the Shaoxing Binhai New Area Biomedical Industry Equity Investment Fund managed by Shengshi Investment and the Shanghai Biomedical Fund. The funds raised will be used to accelerate the research, development, and registration of AccuPulse's core products and to advance the localization of pulsed ablation and three-dimensional mapping systems in China.
 

Public information shows that AccuPulse is a platform-based innovative technology company in the field of cardiac electrophysiology.
 

　　Tianjing Biotechnology: Completed C Round Financing of 500 Million RMB
 

In early February, Tianjing Biotechnology announced the completion of a C1 round of financing exceeding 500 million RMB. This round of financing was jointly invested by Tylon Investment, Zhejiang Province's "4+1" Biomedical and High-end Equipment Industry Fund, I-Mab, Hangzhou Qiantang New City Development Technology Service Co., Ltd., Bruggemoon Limited, and Ningbo KaiTou Hanrun Capital.
 

Public information shows that Hangzhou Tianjing Biotechnology is an innovative biopharmaceutical R&D company, mainly focusing on products in the fields of diabetes, oncology, and autoimmune diseases.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.